Hostname: page-component-7b7567c8c-w7t8q Total loading time: 0 Render date: 2026-11-18T08:27:30.347Z Has data issue: false hasContentIssue false

Unique molecular markers in human endometriosis: implications for diagnosis and therapy

Published online by Cambridge University Press:  12 February 2004

Rosalyn D. Blumenthal
Affiliation:
Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA.
Alice Taylor
Affiliation:
Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA.
Michael Samoszuk
Affiliation:
Quest Diagnostics Inc., 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA.
David M. Goldenberg
Affiliation:
Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Endometriosis originates in the uterine lining and affects ~20% of reproductive-age women. The disease often causes chronic pelvic pain, affects ovulatory function and influences fertility. Although laparoscopic diagnosis of uterine endometriosis is quite specific, direct visualisation can be difficult or inaccurate in some circumstances, and it is not useful for diagnosing extra-abdominal disease. Laparoscopy is an invasive procedure, has significant morbidity and cannot be carried out frequently to monitor efficacy of therapy and the possibility of recurrence. Thus, a specific, non-invasive diagnostic test is required. One intriguing area of research uses the technology of radioimmunotargeting, which has previously been used for cancer detection. This technique could have potential for the specific detection and eventual treatment of endometriosis. A marker, eosinophil peroxidase (EPO), has been identified that is expressed in ~90% of endometriosis specimens, and is not expressed or only weakly expressed in normal endometrium. The US Food and Drug Administration has approved a monoclonal antibody to EPO for investigation as an immunoimaging agent in cancers that exhibit eosinophilia. EPO targeting using this antibody could be useful for detecting and/or treating endometriosis.

Information

Type
Review Article
Copyright
© Cambridge University Press 2001